SCHEMBL8627138

SCHEMBL8627138

c1nc2c(ccc3scnc32)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
MELK Q14680 1/20 0.35
PARP1 P09874 1/20 0.35
ALDH1A1 P00352 4/20 0.35
DPP4 P27487 2/20 0.35
PKM P14618 1/20 0.35
MAPT P10636 2/20 0.33
PRNP P04156 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.32
KDM4E B2RXH2 2/20 0.32
DPP8 Q6V1X1 1/20 0.32
EGFR P00533 1/20 0.31
MMP12 P39900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160632 0.78 ALDH1A1 (0.46) EGLN1MELKALDH1A1HSD17B10KDM4E
SCHEMBL28824630 0.72 LMNA (0.38) LMNAMEN1KMT2APOLBPARP1
SCHEMBL29467245 0.72 LMNA (0.38) LMNAMEN1KMT2APOLBPARP1
SCHEMBL8627135 0.72 MELK (0.37) MEN1KMT2AMELKPARP1ALDH1A1
SCHEMBL10967425 0.65 PDE3B (0.44) EGLN1PARP1
SCHEMBL10054252 0.64 ALDH1A1 (0.38) EGLN1MELKALDH1A1HSD17B10
SCHEMBL12446804 0.64 LMNA (0.53) LMNAMEN1KMT2APOLBPARP1
SCHEMBL9374144 0.63 LMNA (0.64) LMNAMEN1KMT2APOLBALDH1A1
Benzimidazole SCHEMBL4324024 0.62 ALDH1A1 (0.66) PARP1ALDH1A1MAPTHPGDHTT
SCHEMBL18909186 0.61 ALDH1A1 (0.46) LMNAALDH1A1MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550130-B2 Benzo-thiazolo-imidazole compounds and uses thereof KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2020-02-04 US claimed
EP-3070092-B1 3-PHENYL-THIAZOLO[3,2-A]BENZIMIDAZOLE DERIVATIVES AS ALDEHYDE DEHYDROGENASE 1 (ALDH-1) MODULATORS FOR THE TREATMENT OF BREAST CANCER OR LEUKEMIA, AND FOR MANIPULATING CULTURED ALDH-1 POSITIVE BREAST CANCER OR LEUKEMIA CELLS UNIV KING SAUD (SA) 2018-11-07 EP claimed
US-20160272652-A1 BENZO-THIAZOLO-IMIDAZOLE COMPOUNDS AND USES THEREOF KING SAUD UNIVERSITY (SA) 2016-09-22 US claimed
EP-3070092-A1 3-PHENYL-THIAZOLO[3,2-A]BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND FOR THE MANIPULATION OF CULTURED ALDEHYDE DEHYDROGENASE 1 (ALDH-1) POSITIVE CANCER CELLS King Saud University (SA) 2016-09-21 EP claimed
US-10550130-B2 Benzo-thiazolo-imidazole compounds and uses thereof KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2020-02-04 US disclosed
US-10550130-B2 Benzo-thiazolo-imidazole compounds and uses thereof KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2020-02-04 US disclosed
US-10550130-B2 Benzo-thiazolo-imidazole compounds and uses thereof KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2020-02-04 US disclosed
EP-3070092-B1 3-PHENYL-THIAZOLO[3,2-A]BENZIMIDAZOLE DERIVATIVES AS ALDEHYDE DEHYDROGENASE 1 (ALDH-1) MODULATORS FOR THE TREATMENT OF BREAST CANCER OR LEUKEMIA, AND FOR MANIPULATING CULTURED ALDH-1 POSITIVE BREAST CANCER OR LEUKEMIA CELLS UNIV KING SAUD (SA) 2018-11-07 EP disclosed
US-20160272652-A1 BENZO-THIAZOLO-IMIDAZOLE COMPOUNDS AND USES THEREOF KING SAUD UNIVERSITY (SA) 2016-09-22 US disclosed
US-20160272652-A1 BENZO-THIAZOLO-IMIDAZOLE COMPOUNDS AND USES THEREOF KING SAUD UNIVERSITY (SA) 2016-09-22 US disclosed
EP-3070092-A1 3-PHENYL-THIAZOLO[3,2-A]BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND FOR THE MANIPULATION OF CULTURED ALDEHYDE DEHYDROGENASE 1 (ALDH-1) POSITIVE CANCER CELLS King Saud University (SA) 2016-09-21 EP disclosed
EP-3070092-A1 3-PHENYL-THIAZOLO[3,2-A]BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND FOR THE MANIPULATION OF CULTURED ALDEHYDE DEHYDROGENASE 1 (ALDH-1) POSITIVE CANCER CELLS King Saud University (SA) 2016-09-21 EP disclosed
EP-0843681-A1 HETEROCYCLE-FUSED THIAZOLE DERIVATIVES YUNGJIN PHARMACEUTICAL CO., LTD. (KR) 1998-05-27 EP disclosed
WO-1997003076-A1 HETEROCYCLE-FUSED THIAZOLE DERIVATIVES YUNGJIN PHARMACEUTICAL CO., LTD. (KR) 1997-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272652-A1 BENZO-THIAZOLO-IMIDAZOLE COMPOUNDS AND USES THEREOF BRD4, TEC, BTK LMNA 3782/4885MEN1 1431/4885KMT2A 2916/4885
US-10550130-B2 Benzo-thiazolo-imidazole compounds and uses thereof TP53, THPO, TBCA LMNA 2160/4885MEN1 582/4885KMT2A 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.